Janssen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?
JANSSEN PHARMS has fifty-eight approved drugs.
There are twenty-nine US patents protecting JANSSEN PHARMS drugs.
There are seven hundred and thirteen patent family members on JANSSEN PHARMS drugs in sixty-five countries and one hundred and two supplementary protection certificates in eighteen countries.
Summary for Janssen Pharms
International Patents: | 713 |
US Patents: | 29 |
Tradenames: | 57 |
Ingredients: | 35 |
NDAs: | 58 |
Drugs and US Patents for Janssen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-006 | Mar 18, 2021 | RX | Yes | No | RE43728 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Pharms | INVEGA HAFYERA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-006 | Aug 30, 2021 | RX | Yes | No | 11,666,697 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | MODICON 28 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 017735-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-007 | Mar 18, 2021 | RX | Yes | No | 10,220,023 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | INVOKAMET | canagliflozin; metformin hydrochloride | TABLET;ORAL | 204353-002 | Aug 8, 2014 | RX | Yes | No | 8,513,202 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Pharms | CONCERTA | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021121-003 | Dec 8, 2000 | 4,519,801 | ⤷ Try a Trial |
Janssen Pharms | RISPERDAL CONSTA | risperidone | INJECTABLE;INTRAMUSCULAR | 021346-002 | Oct 29, 2003 | 6,403,114*PED | ⤷ Try a Trial |
Janssen Pharms | LEVAQUIN | levofloxacin | SOLUTION;ORAL | 021721-001 | Oct 21, 2004 | 5,053,407*PED | ⤷ Try a Trial |
Janssen Pharms | DITROPAN XL | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 020897-001 | Dec 16, 1998 | 6,124,355*PED | ⤷ Try a Trial |
Janssen Pharms | RISPERDAL CONSTA | risperidone | INJECTABLE;INTRAMUSCULAR | 021346-004 | Apr 12, 2007 | 6,403,114*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
International Patents for Janssen Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1103235 | ⤷ Try a Trial |
New Zealand | 547962 | ⤷ Try a Trial |
Norway | 20060219 | ⤷ Try a Trial |
Israel | 212351 | ⤷ Try a Trial |
China | 117137912 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1429780 | SPC/GB12/058 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
0605697 | SPC/GB01/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
1261606 | 48/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: RIVAROXABAN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/08/472/001 - EU/1/08/472/008 20080930 |
1651658 | PA2014008 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115 |
3256125 | 122022000027 | Germany | ⤷ Try a Trial | PRODUCT NAME: PONESIMOD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1550 20210519 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.